#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Immunodeficiency common variable Mantle cell lymphoma stage III Hormone-dependent prostate cancer Splenic marginal zone lymphoma Myeloproliferative neoplasm Juvenile chronic myelomonocytic leukaemia Cardiac failure acute Chronic granulomatous disease Hypereosinophilic syndrome Anaplastic thyroid cancer Hepatic angiosarcoma Palmoplantar pustulosis Cutaneous T-cell lymphoma recurrent Tourette's disorder Optic glioma More trials…

    Learn about Rare Diseases

    Glycogen storage disease type V – Basic Information Familial amyotrophic lateral sclerosis – Trials in Disease Usher’s syndrome – Diagnostics Mucopolysaccharidosis – Trials in Disease Fabry’s disease – Treatment Short-bowel syndrome – Trials in Disease Krabbe’s disease Mantle cell lymphoma refractory Ehlers-Danlos syndrome – Trials in Disease Sarcoidosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Diroximel Fumarate ATTR-01 Zofenopril Calcium Acetylcholine Chloride Lactic Acid Losartan Potassium E2814 Rp-1664 Sulfate SONLICROMANOL HYDROCHLORIDE Etelcalcetide Romiplostim Abacavir Pitolisant Peppermint Oil Tavapadon Meglumine Gadoterate [18F]Fluoro-Peg-Folate Alternaria Alternata (402) Aprepitant Crd-4730 More therapies…

    Learn about Your Condition

    Lennox-Gastaut syndrome Follicular thyroid cancer Adenocarcinoma gastric Progressive multiple sclerosis Prader-Willi syndrome Dermatitis atopic Acute myeloid leukaemia Colorectal adenoma Small cell lung cancer Skin disorder Systemic sclerosis pulmonary Metastatic neoplasm Lipid metabolism disorder Hypoglycaemia Arteriosclerosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive breast cancer

  • Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Exemestane
    Germany

  • Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer female
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    Germany

  • Study on Elacestrant and Triptorelin for Premenopausal Women with Early Luminal Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Elacestrant Dihydrochloride
    • Tamoxifen Citrate
    • Triptorelin Acetate
    Spain

  • Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer male
    • Human epidermal growth factor receptor negative
    • Breast cancer
    Investigated Drugs:
    • Elacestrant
    • Ribociclib
    Austria Germany Spain

  • A Study of Camizestrant and Ribociclib for Patients with Hormone Receptor-Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Camizestrant
    • Ribociclib
    Germany Spain

  • Study on Everolimus and Exemestane for Patients with Metastatic Breast Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Exemestane
    • Everolimus
    Hungary
Previous Page
1 2 3 4 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!